Active substanceOmeprazoleOmeprazole
Similar drugsTo uncover
  • Gastrozole®
    capsules inwards 
  • Gastrozole®
    capsules inwards 
    OTISIFARM, OJSC     Russia
  • Zhelezol®
    lyophilizate d / infusion 
  • Losek®
    lyophilizate d / infusion 
    AstraZeneca UK Ltd     United Kingdom
  • Losek® MAPS®
    pills inwards 
    AstraZeneca AB     Sweden
  • Omal
    lyophilizate in / in 
    FARMGID CJSC     Russia
  • Omez®
    lyophilizate d / infusion 
  • Omez
    capsules inwards 
  • Omez® Insta
    powdersuspension inwards 
  • Omeprazole
    capsules inwards 
    OZONE, LLC     Russia
  • Omeprazole
    capsules inwards 
    BIOSINTEZ, PAO     Russia
  • Omeprazole
    capsules inwards 
  • Omeprazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Omeprazole
    capsules
  • Omeprazole
    capsules inwards 
  • Omeprazole
    capsules inwards 
    LEKFARM, SOOO     Republic of Belarus
  • Omeprazole
    capsules inwards 
    AVVA RUS, OJSC     Russia
  • Omeprazole
    capsules inwards 
    SYNTHESIS, OJSC     Russia
  • Omeprazole
    lyophilizate d / infusion 
    Life Sainses OHCF     Russia
  • Omeprazole
    lyophilizate d / infusion 
    ALVILS, LTD.     Russia
  • Omeprazole Zentiva
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Omeprazole Stada
    capsules inwards 
    NIZHFARM, JSC     Russia
  • Omeprazole-OBL
    capsules inwards 
  • Omeprazole-Acrychin®
    capsules inwards 
    AKRIKHIN HFK, JSC     Russia
  • Omeprazol-Richter
    capsules inwards 
  • Omeprazole-C3
    capsules inwards 
    NORTH STAR, CJSC     Russia
  • Omeprazole-Teva
    capsules inwards 
  • Omizak ®
    capsules inwards 
  • Omitox
    capsules
  • Ortanol®
    lyophilizate d / infusion 
    Sandoz d.     Slovenia
  • Ortanol®
    capsules inwards 
    Sandoz d.     Slovenia
  • Pleom-20
    capsules inwards 
  • Pomez
    capsules inwards 
  • Romesque®
    capsules inwards 
  • Ulcozol®
    capsules inwards 
    VALEANT, LLC     Russia
  • Ultop®
    capsules inwards 
  • Ultop®
    lyophilizate d / infusion 
  • Ultop®
    capsules inwards 
  • Helicid®
    lyophilizate d / infusion 
    Zentiva c.s.     Czech Republic
  • Cisagast
    capsules inwards 
    PRO.MED.CS Prague as.     Czech Republic
  • Dosage form: & nbsp

    lyophilizate for solution for infusion

    Composition:

    1 bottle contains:

    Active substance:

    Omeprazole 40,000 mg Excipients:


    1N sodium hydroxide solution 0.132 ml, disodium edetate 1,000 mg, water for injection q.s.* 2,000 ml is removed during lyophilization

    Description:

    lyophilized mass of white or almost white color.

    Pharmacotherapeutic group:a means of reducing the secretion of the glands of the stomach - a proton pump inhibitor.
    ATX: & nbsp

    A.02.B.C.01   Omeprazole

    Pharmacodynamics:

    Inhibits the enzyme H + K + ATP-ase ("proton pump") in parietal cells of the stomach and blocks the final stage of the synthesis of hydrochloric acid. This leads to a decrease in the level of basal and stimulated secretion, regardless of the nature of the stimulus. After a single administration of the drug, the pharmacological effect persists for 24 hours.

    Pharmacokinetics:

    The connection with plasma proteins is 95%. Omeprazole almost completely metabolized in the liver. It is an inhibitor of the enzyme system CYP2C19. The half-life after intravenous administration is 40 minutes and does not change with prolonged treatment. Kidney excretion (70-80%) and with bile (20-30%).In chronic renal failure, excretion decreases in proportion to a decrease in creatinine clearance.

    Indications:

    - Peptic ulcer of the stomach and duodenum;

    - Reflux esophagitis;

    - Erosive and ulcerative lesions of the stomach and duodenum associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), stress ulcers;

    - Erosive-ulcerative lesions of the stomach and duodenum, associated with Helicobacter pylori (in combination with antibiotics, as part of complex therapy);

    - Zollinger-Ellison syndrome;

    Prevention of ingestion of acidic stomach contents in the respiratory tract during general anesthesia (Mendelssohn syndrome).
    Contraindications:

    Hypersensitivity to the drug, children's age, lactation.

    Carefully:

    renal and / or liver failure.

    Pregnancy and lactation:

    Care should be taken when prescribing the drug to pregnant women. Treatment is indicated in cases where the potential beneficial effect of the drug on the mother's body justifies the risk to the fetus. During treatment, breastfeeding is not recommended.

    Dosing and Administration:

    If it is not possible to perform oral therapy for patients with stomach ulcers and duodenal ulcers or reflux esophagitis, intravenous administration of Ultop should be given at a dose of 40 mg once daily. Patients with Zolinger-Ellison syndrome are recommended initial intravenous administration of Ultopa at a dose of 60 mg per day. Doses are selected individually, sometimes a higher dose is required. If the daily dose exceeds 60 mg, the dose should be divided into two injections.

    The infusion solution of Ultop is administered intravenously drip for 20-30 minutes. It is recommended to inject the infusion solution immediately after its preparation. Patients with impaired renal function - there is no need to adjust the dose. Patients with impaired liver function - the half-life of omeprazole is longer, it is recommended to reduce the daily dose to 10-20 mg.

    To patients of advanced age no dose adjustment is required.

    Preparation of Ultop infusion solution. *

    Dissolve lyophilized powder of omeprazole in 100 ml of 5% infusion solution of dextrose (glucose) or in 100 ml infusion saline. Infusion solution on 5% dextrose should be used within 6 hours.The infusion solution in physiological saline should be used within 12 hours.

    Side effects:

    On the part of the digestive system: diarrhea or constipation, nausea, vomiting, flatulence, abdominal pain, dry mouth, taste disorders, stomatitis, transient increase in the activity of "liver" enzymes in the plasma; in patients with a previous severe liver disease - hepatitis (including jaundice), a violation of liver function.

    From the nervous system: headache, dizziness, agitation, drowsiness, insomnia, paresthesia, depression, hallucinations; in patients with severe concomitant somatic diseases, patients with previous severe liver disease - encephalopathy.

    From the musculoskeletal system: muscle weakness, myalgia, arthralgia.

    On the part of the hematopoiesis system: leukopenia, thrombocytopenia; in selected

    cases - agranulocytosis, pancytopenia.

    From the skin: itching, skin rash; in some cases -

    photosensitization, multiforme exudative erythema, alopecia.

    Allergic reactions: urticaria, angioedema, bronchospasm,

    interstitial nephritis, anaphylactic shock, fever.

    Other: impaired vision, peripheral edema, increased sweating,

    gynecomastia; rarely - the formation of gastric glandular cysts during long-term treatment (the consequence of inhibition of the secretion of hydrochloric acid, is benign, reversible).

    If Ultop is used for a short period of time, the side effect is rarely seen and is of a weak and transient nature. Most often, side effects are noted at the beginning of treatment. During prolonged treatment, the incidence of side effects decreases. Side effects of severe severity are very rare. If they develop, treatment should be interrupted. The incidence of side effects in patients older than 65 years is the same as in younger patients.

    Overdose:

    Symptoms: pain in the abdominal region, drowsiness, headache, dizziness, increased sweating, dry mouth, palpitations, impaired vision. Cramps, difficulty breathing and lowering of body temperature are possible.

    There is no specific antidote. Treatment is symptomatic. Hemodialysis is not effective enough.

    Interaction:

    The interaction of omeprazole with other medications is rare. There is a possibility of interaction with drugs that are metabolized in the liver with the enzyme of the cytochrome P450 system. Concentrations in blood plasma diazepam, phenytoin, nifedipine, warfarin, aminopyrine, antipyrine and disulfiram can increase. As a rule, this increase is clinically insignificant for usual doses of omeprazole. Nevertheless, it is recommended that patients be monitored when Ultop is started or stopped, and if necessary, phenytoin, diazepam, warfarin and disulfiram.

    With simultaneous appointment clarithromycin the concentrations of clarithromycin and omeprazole in the blood serum increase.

    An increase in the pH of the gastric juice can lead to a decrease in bioavailability ampicillin, ketoconazole, itraconazole and preparations of iron.

    Simultaneous administration of omeprazole and digoxin to healthy people increases the bioavailability of digoxin by 10% due to the elevated pH in the stomach. Efficiency prednisolone and cyclosporine can be reduced. Therefore, sometimes you need to adjust the dose of cyclosporine.

    With the simultaneous administration of antacids, amoxicillin, digoxin, theophylline, lidocaine, quinidine, metoprolol, or propranolol, no clinically significant interaction has been established.

    Special instructions:

    Before the start of therapy, it is necessary to exclude the presence of malignant process (especially with gastric ulcer), because treatment, masking the symptoms, can delay the establishment of the correct diagnosis.

    For elderly patients, dose adjustment is not required. Bioavailability of omeprazole is increased in patients with cirrhosis, but no increase in toxicity was noted. The daily dose should not exceed 20 mg.

    For patients with kidney disease, dose adjustment is not required. Dialysis in patients with chronic kidney disease does not affect the pharmacokinetic properties of omeprazole.

    Effect on the ability to drive transp. cf. and fur: In normal dosages, the drug does not affect the speed of psychomotor reactions and concentration of attention.
    Form release / dosage:

    Lyophilizate for the preparation of a solution for infusions in a vial of colorless glass containing 40 mg of omeprazole, capped with a rubber stopper,an aluminum cap and a plastic protective cover.

    Packaging:One bottle together with the instruction for use is placed in a cardboard box.
    Storage conditions:

    Store at a temperature of no higher than 25 ° C, in a place protected from light.

    Keep out of the reach of children.

    Shelf life:

    2 of the year.

    Do not use the drug after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002262/07
    Date of registration:17.08.2007
    The owner of the registration certificate:KRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Manufacturer: & nbsp
    Representation: & nbspKRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Information update date: & nbsp04.10.2013
    Illustrated instructions
      Instructions
      Up